Sulfadoxine D3
(Synonyms: Sulphadoxine D3) 目录号 : GC67935Sulfadoxine D3 是 Sulfadoxine 的氘代物。Sulfadoxine 是一种磺酰胺类化合物，通常与 Pyrimethamine 联合用于耐多药恶性疟原虫和间日疟原虫的防治。但与 Pyrimethamine 不同，Sulfadoxine 对 HIV 的复制和 MT-2 细胞周期进展没有影响。Sulfadoxine 还能抑制呼吸道、泌尿道感染。
Cas No.:1262770-70-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sulfadoxine D3 is a deuterium labeled Sulfadoxine . Sulfadoxine is a sulfonamide that is used, usually in combination with Pyrimethamine , for multidrug-resistant Plasmodium falciparum and P. vivax inhibition. Unlike PYR, Sulfadoxine has no impact on HIV replication or MT-2 cell cycle progression. But also Sulfadoxine exhibits suppression on respiratory, and urinary tract infections[1][2][3][4].
磺胺多辛 (0-100 μM;7 d) 对 MT-2 细胞中 HIV-1 的复制无影响[4].
磺胺多辛 (100 μM;48 h) 对 MT-2 细胞 S 期积累的诱导无影响[4].
磺胺多辛 (0.1, 0.3, 10 mg/kg/d; 口服; 每日1次, 连用 3天) 与阿奇霉素 (30 mg/kg/d; 口服; 每日1次, 连用 3天)，能够抑制小鼠疟疾模型中的血期寄生虫或约氏疟原虫子孢子[5].
[1]. Ratcliff A, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007 Apr;101(4):351-9.
[2]. Fey K, et al. Empfindlichkeit bakterieller Krankheitserreger aus dem Respirationstrakt von Pferden gegenÜber Trimethoprim, Sulfadoxin, Sulfadimethoxin und Kombinationen dieser Wirkstoffe [Susceptibility of bacterial isolates from the equine respiratory tract to trimethoprim, sulfadoxine, sulfadimethoxine and combinations of these compounds]. Tierarztl Prax. 1995 Apr;23(2):148-54. German.
[3]. Baraff LJ. Emergency medicine-important advances in clinical medicine: single-dose treatment of urinary tract infections. West J Med. 1983 Jan;138(1):89-90.
[4]. Oguariri RM, et al. Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication. Virus Res. 2010 Nov;153(2):269-76.
[5]. Neerja J, et al. Plasmodium yoelii: activity of azithromycin in combination with pyrimethamine or sulfadoxine against blood and sporozoite induced infections in Swiss mice. Exp Parasitol. 2004 Jul-Aug;107(3-4):120-4.
| Cas No. | 1262770-70-6 | SDF | Download SDF |
| 别名 | Sulphadoxine D3 | ||
| 分子式 | C12H11D3N4O4S | 分子量 | 313.35 |
| 溶解度 | DMSO : ≥ 100 mg/mL (319.13 mM); H2O : 0.1 mg/mL (0.32 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1913 mL | 15.9566 mL | 31.9132 mL |
| 5 mM | 0.6383 mL | 3.1913 mL | 6.3826 mL |
| 10 mM | 0.3191 mL | 1.5957 mL | 3.1913 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria
Am J Ther 2012 Sep;19(5):338-45.PMID:19918170DOI:10.1097/MJT.0b013e3181baf266.
Sulfadoxine (SDX)-pyrimethamine is currently recommended as a partner drug with artesunate in the chemotherapy of malaria. However, information on pharmacokinetic disposition of SDX-pyrimethamine in children is limited. Efforts in this study were thus devoted to evaluation of pharmacokinetic disposition of SDX using high-pressure liquid chromatographic techniques and effects of pharmacokinetic variability on treatment outcome in Nigerian children with falciparum malaria. The blood concentration profile of SDX was similar in patients whose infection responded to treatment and those who failed treatment; mean SDX concentration values were similar for day 3 (179 vs 157 μg/mL, P = 0.734), day 7 (84 vs 51 μg/mL, P = 0.365), and day 14 (50 vs 14 μg/mL, P = 0.151). Extent of exposure (area under the curve) to SDX was also similar in the patients (1196 vs 1013 μg d/mL, P = 0.561). Pearson's correlation, showed significant correlation between area under the curve and D3 or D7 concentration of SDX (P = 0.001, r = 0.702 or P = 0.001, r = 0.835, respectively). Age-stratified analysis showed that SDX concentrations were significantly higher in older children (older than 5 years); the mean maximum concentration (125 vs 295 μg/mL, P = 0.001), extent of exposure (812 vs 1562 μg d/mL, P = 0.001), day 3 concentration (98 vs 250 μg/mL, P = 0.001), and day 7 concentration (54 vs 128 μg/mL, P = 0.007) were higher. The study revealed no differences in posttreatment blood SDX concentrations in patients who responded to treatment and those who failed to respond to treatment. Furthermore, there was an age-related pharmacokinetic variability of SDX in the group of children studied with potential impact on treatment outcome.